Only 15,000 scripts per month would see BOT net sales at about $100m. I don’t think it’ll be too hard to take that market share from Qbrexza and Botox. Drysol is way cheaper, but also way less effective. I reckon BOT will probably attract a fair share of otherwise untreated sufferers too! $100m net with a 20xPE (like NEU) would see BOT above $1, just on Sofdra alone.
Only 15,000 scripts per month would see BOT net sales at about...
-
- There are more pages in this discussion • 3,473 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.005(1.19%) |
Mkt cap ! $742.1M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 40.0¢ | $2.133M | 5.181M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500000 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 341870 | 4 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |